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Until the middle of the twentieth century, analyses of long-run macroeconomic performance were based on an aggregate production function of the form:
where Y = real GDP (the market value of goods and services produced)
Capital is, of course, a produced means of production, which accumulates according to the perpetual inventory equation K t+1 = (1 -δ) K t + I t , where δ is the depreciation rate and I denotes investment.
In the last 50 or 60 years, economists have recognized the inadequacies of this production function-its failure to account for important aspects of observed macroeconomic behavior-and have modified and extended it in several ways. The most important modifications have been expansions of the sets of both inputs and outputs accounted for.
By the 1950s, economists realized that most of the growth in output could not be accounted for by growth in capital and labor. Most output growth was due to total factor productivity (TFP) growth-growth in output per unit of total input-which is not accounted for in eq.
(1). Growth in TFP was hypothesized to be due to technological progress. The production function could easily be modified to allow for the existence of technological progress:
where A = an index of the level of technology.
Solow (1956) demonstrated that in the long run, the growth rate of per capita output would be equal to the rate of technological progress (the growth rate of A). In that paper, Solow assumed that technological progress was exogenous: it descends upon the economy like "manna from heaven," automatically and regardless of whatever else is going on in the economy (Jones (1998, 32-3) ). But subsequent investigators have hypothesized and provided evidence that productivity growth and technological progress is endogenous-determined by investment in research and development (R&D). The dependence of technical progress on R&D is a key feature of recent theoretical ("endogenous growth") models (Romer (1990) ).
Griliches proposed the following model to incorporate endogenous (R&D-generated) technical change into the production function:
where Z = the stock of "knowledge capital"
Like physical capital, knowledge capital is a produced means of production, which accumulates according to the perpetual inventory equation Z t+1 = (1 -δ Z ) Z t + RD t , where δ Z is the knowledge-capital depreciation rate and RD denotes R&D investment.
There are two ways in which one can use eq. (3) to assess the contribution of knowledge capital to productivity growth. One is to examine the relationship (e.g., across industries) between TFP growth and the growth of Z. The other is to examine the relationship between TFP growth and "R&D-intensity" (the ratio of R&D investment to output). 1 Under certain reasonable assumptions, the R&D-intensity coefficient in the 1 The second approach does not require a long history of R&D investment or an estimate of the initial knowledge-capital stock.
TFP regression is an estimate of the marginal product of knowledge capital, and of the rate of return to investment in R&D.
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Numerous empirical studies (e.g. Griliches and Lichtenberg (1984), Lichtenberg and Siegel (199?) ) have provided strong support for the hypothesis that R&D has contributed significantly to growth in the market value of goods and services produced.
But economists believe that the utility, or welfare, of individuals and nations depends not only on the goods and services they consume but also on the amount of (leisure) time Suppose, for simplicity, that p l remains constant over time. Then
The change in full income is the change in GDP plus the change in the value of leisure time consumed. During the last century, longevity increase has been an important source of increase in the average person's leisure time over the course of the life cycle.
Nordhaus (2002) estimated that, "to a first approximation, the economic value of increases in longevity over the twentieth century is about as large as the value of measured growth in non-health goods and services" (p. 17). 3 In other words, his estimates imply that ∆Y ≈ p L ∆L.
Due to the importance of leisure time in general, and longevity in particular, to economic well-being, we propose replacing GDP in the production function by "full income":
We hypothesize that R&D-generated increases in the stock of knowledge capital (Z) may have a positive impact on both components of full income: leisure time (via longevity) and consumption of goods and services. According to the NSF, in 1996 16% of U.S.
R&D was associated primarily with the life sciences; this share increased from 12% in
1985.
In the next section we discuss the measurement of pharmaceutical knowledgecapital accumulation. In section 2 we postulate an econometric model of the effect of pharmaceutical knowledge-capital accumulation on the age distribution of deaths.
Measurement of changes in the age distribution of deaths, by cause of death, is discussed in section 3. Empirical results are reported in Section 4, and section 5 presents a summary and conclusions.
Measurement of pharmaceutical knowledge-capital accumulation
The basic hypothesis we wish to investigate is that pharmaceutical R&D investment has increased the longevity of Americans:
3 "The Health To explain the relationship between R&D investment and new drug approvals, and why the latter is a superior indicator for explaining changes in longevity, it is useful to briefly describe the process of drug development.
The FDA's depiction of the new drug development timeline is shown in Figure 1 .
There are three main phases of drug development up until the time of new drug approval.
The first phase is pre-clinical testing, research and development, including testing in animals. According to the FDA, the average duration of this phase is 18 months. In order to proceed to the second stage, the drug sponsor must submit, and receive FDA approval of, an investigational new drug (IND) application. Upon approval of the IND, the sponsor may begin clinical R&D (human trials).
4 "FDA estimates that, on average, it takes eight-and-a-half years to study and test a new drug before the agency can approve it for the general public. That includes early laboratory and animal testing, as well as later clinical trials using human subjects. According to the FDA, the average duration of the NDA review process is 2 years.
The FDA says that of 100 drugs for which investigational new drug applications are submitted, about 70 percent will successfully complete phase 1 and go on to phase 2; about 33 percent of the original 100 will complete phase 2 and go to phase 3; and 25 to 30 of the original 100 will clear phase 3 (and, on average, about 20 of the original 100 will ultimately be approved for marketing). This is consistent with 1990-2001 data on the number of commercial 5 INDs received and NDAs received and approved shown in Figure 2 . The average annual number of NDAs approved (85) Are patent data likely to be useful? R&D and patenting are known to be closely related. 11 Perhaps patent data could supersede most of the limitations of the R&D data.
The U.S. Patent and Trademark Office (USPTO) publishes data on the number of patents granted for "drug, bio-affecting and body treating compositions" (patent class 514). Figure 5 presents annual data on the number of "drug patents" (patents in cla ss 514) and total patents granted from 1980 to 2000. Drug patents do exhibit somewhat more variability than R&D expenditure. 12 However drug patents track total patents quite closely.
Disaggregation of drug patents by therapeutic action appears to be infeasible.
Although certain subclasses of class 514 pertain to specific diseases (e.g. subclass 866
refers to diabetes, and subclass 883 refers to Hodgkin's disease 13 ), these subclasses are "cross-reference art collections", and drug patents are not systematically classified by disease or therapeutic action.
14 11 See R&D, Patents, and Productivity, ed. by Zvi Griliches. 12 The R 2 of the regression of the drug patent series on an exponential trend is .8897. 13 See http://www.uspto.gov/go/classification/uspc514/sched514.htm. 14 The seventh (1999) edition of the International Patent Classification system appears to provide (in class A61P) a systematic classification of chemical compounds and medicinal preparations by therapeutic activity. For example subclass 1/ 00 includes drugs for disorders of the alimentary tract or the digestive system, and subclass 1/18 covers drugs for pancreatic disorders, e.g. Sample data from the NDDF Drug Indications Master Table, for two indications-tuberculosis and hypercholesterolemia-are shown in Table 1 . 20 The table lists 11 drugs appropriate for the treatment of tuberculosis, and 14 drugs appropriate for the treatment of hypercholesterolemia. All of the tuberculosis drugs are designated as "labeled", but three of the hypercholesterolemia drugs are designated as "unlabeled".
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According to the American Medical Association's Council on Scientific Affairs, Unlabeled uses are defined as the use of a drug product for indications or in patient populations, doses, or routes of administration that are not included in FDA-approved labeling. The prevalence and clinical importance of prescribing drugs for unlabeled uses are substantial. Unlabeled indications are especially common in oncology, rare diseases, and pediatrics. Thus, the prescribing of drugs for unlabeled uses is often necessary for optimal patient care.
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We will construct estimates of the stock of drugs available to treat specific conditions, both excluding and including unlabeled indications.
The NDDF Drug Indications Master using another unpublished FDA data file and data posted on the FDA website. The FDA data on NME approvals are illustrated in Table 2 , which shows NMEs approved in calendar year 2000.
We aggregated the data in the NDDF Drug Indications Master Table up to the (approximately) 2-digit ICD9 level, to be consistent with the CDC Mortality Data (described below). There is considerable variation across diseases-even diseases in the same broad disease groups-in the extent and timing of increases in the stock of available drugs. This is illustrated by Figure 6 , which shows, for two conditions-diseases of the thyroid gland and diseases of other endocrine glands-the number of drugs available to treat the condition in year t, as a percent of the number of drugs available to treat the condition in 1979. 23 Between 1979 and 1984, the number of drugs available to treat diseases of the thyroid gland increased 29%, while the number of drugs available to treat diseases of other endocrine glands increased only 13%. However, between 1984 and 1998, the number of drugs available to treat diseases of the thyroid gland did not increase at all, while the number of drugs available to treat diseases of other endocrine glands increased 33%.
The algorithm we adopted is based on the assumption that a drug linked to a condition in the NDDF Drug Indications Master Table became available to treat the condition in the year that the drug was first approved as an NME by the FDA. We know that this assumption is incorrect in at least some cases, because some of a drug's indications may be added years after the drug was first approved as an NME. Table 3 provides examples of New Indication approvals, and the predecessor NME approvals.
Amantadine hydrochloride was initially approved as an NME in 1966, and designated as an antiviral/anti-influenza/systemic drug. Seven years later, a new indication of the drug was approved by the FDA, and it was also classified as an anti-parkinson drug.
Unfortunately, although we have complete data on NME approvals, data on New 23 In 1979, there were 7 drugs for treating diseases of the thyroid gland, and 38 drugs for treating diseases of other endocrine glands Indication approvals are incomplete. Even if complete data on New Indication approvals by the FDA were available, in light of extensive unlabeled drug use, it is not clear how they should be used. A drug approved as an NME might be frequently prescribed for many years for a condition that is "off-label".
When the FDA receives a New Drug Application, it assesses the drug's "therapeutic potential", and classifies it as either a "Priority Review" drug-one that represents a "significant improvement compared to marketed products, in the treatment, diagnosis, or prevention of a disease"-or a "Standard Review" drug-one that "appears to have therapeutic qualities similar to those of one or more already marketed drugs."
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Two diseases that have similar increases in the total number of NMEs approved may have quite different increases in the number of priority review NMEs approved. For example, 16 drugs for treating ICD9 code 090 were approved during 1979-1998, but only 5 (31%) of these were priority review drugs. The total number of drugs approved for treating ICD9 code 200 was lower-14-but 10 (71%) of these drugs were priority review drugs. In our empirical analysis, we will distinguish between the stock of priority review drugs available to treat a condition and the stock of standard review drugs available.
Model
The basic model we will estimate is:
where:
MORT it = an indicator of mortality (e.g., mean age at death) from ICD9 disease i (i = 00, 01, …, 99) in year t (t = 1979, 1980,…, 1998) DRUG_STOCK it = the stock of drugs available to treat disease i in year t 24 Applications for new indications are also classified by therapeutic potential, and the therapeutic potential of a new indication may differ from the therapeutic potential of the NME.
The fixed disease effects (α i 's) control for any determinants of mortality that vary across diseases but do not vary over time. The year effects (δ t 's) control for any determinants of mortality that vary over time but do not vary across diseases. If the estimate of β is positive and significant, that indicates that diseases with above-average increases in the stock of drugs had above-average changes in the mortality indicator.
We can allow for different effects of priority-review and standard-review drug approvals by estimating the more general model:
PRI_STOCK it = the stock of priority-review drugs available to treat disease i in year t STD_STOCK it = the stock of standard-review drugs available to treat disease i in year t
We think it is worthwhile to briefly discuss how this model relates to the literature on endogenous technical change and on embodiment. The production function for output is:
The production function for ideas is:
where 0 < λ < 1 and φ may be either positive or negative. The DRUG_STOCK variable corresponds to Romer's "stock of ideas" variable (A). In the empirical analysis, we count only the "ideas" (new molecular entities) that have been approved by the FDA. that "each successive vintage of investment is more productive than the last." Equipment is expected to embody significant technical progress due to the relatively high R&D-intensity of equipment manufacturers. According to the National Science Foundation, the R&D-intensity of machinery and equipment manufacturing is about 50% higher than the R&D-intensity of manufacturing in general, and 78% higher than the R&D intensity of all industries.
One method that has been used to test the equipment-embodied technical change hypothesis is to estimate manufacturing production functions, including (mean) vintage of equipment as well as quantities of capital and labor. Bahk and Gort (1993) Figure 7 shows the number of original PMAs reviewed by the FDA during the period 1981-2001.
One characteristic is the identity of the Advisory Committee that has jurisdiction over the device. As Table 4 indicates, there are nineteen Advisory Committees, but two committees account for more than half of all original PMAs. 26 Moreover, it would be difficult to construct a "mapping" from PMAs classified by Advisory Committee to mortality data classified by ICD9 code. PMAs are also classified by "Product Code", but the number of distinct Product Codes is extremely large (almost as large as the number of PMAs--over 5000), they do not appear to be hierarchically organized, and it would be difficult to construct a "mapping" from Product Codes to ICD9 codes. (Unfortunately, neither First DataBank nor anyone else produces a Device Indications Master Table. ) 27 Suppose that mortality from disease i in year t depends on the stocks of both drugs and devices approved to treat that disease. We can measure the stock of drugs, but due to the data limitations just described, we cannot measure the stock of devices. If changes in the stock of devices are uncorrelated across diseases with changes in the stock of drugs, the drug-stock coefficient is unbiased. If changes in the stocks of devices and drugs are correlated, the drug-stock coefficient is biased. The direction of bias depends on the sign of the correlation. If the change in the stock of devices is negatively 26 Over 90% of PMAs are "supplemental" PMAs: applications to modify the design, manufacturing, or other aspects of original PMAs. 27 The PMA database includes "device description / indications" information, but disease coding of this information would be challenging and costly. Here is sample information about PMA Number P010054, Approval for the Elecsys Anti-HBs Immunoassay and Elecsys PreciControl Anti-HBs: "The Elecsys AntiHBs Immunoassay is indicated for: The qualitative determination of total antibodies to the hepatitis B surface antigen (HBsAg) in human serum and plasma (EDTA). The electrochemilumin-escence immunoassay "ECLIA" is intended for use on the Roche Elecsys 2010 immunoassay analyzer. Assay results may be used as an aid in the determination of susceptibility to hepatitis B virus (HBV) infection for individuals prior to or following HBV vaccination, or where vaccination status is unknown. Assay results may be used with other HBV serological markers for the laboratory diagnosis of HBV disease associated with HBV infection. A reactive assay result will allow a differential diagnosis in individuals displaying signs and symptoms of hepatitis in whom etiology is unknown. The detection of anti-HBs is indicative of laboratory diagnosis of seroconversion from hepatitis B virus (HBV) infection. The Elecsys PreciControl Anti-HBs is indicated for: The preciControl Anti-HBs is used for quality control of the Elecsys Anti-HBs immunoassay on the Elecsys 2010 immunoassay analyzer. The performance of the PreciControl Anti-HBs has not been established with any other Anti-HBs assay." correlated across diseases with the change in the stock of drugs, the drug-stock coefficient is downward biased. Some evidence suggests that this correlation may indeed be negative. Lichtenberg (1996 Lichtenberg ( , 2001 presented evidence that use of newer drugs is associated with lower utilization of hospital care. Since use of some medical devices, such as stents and artificial hearts, requires hospitalization, drugs and devices may be substitutes rather than complements.
Measurement of changes in the age distribution of deaths, by cause of death
We used the Compressed Mortality File (CMF) to measure changes in the age The system used to classify deaths changed in 1979 and again in 1999. The three classification schemes are different enough so as to make direct comparisons of cause of death difficult, so our analysis is confined to the period 1979-1998. 28 Counts and rates of death can be obtained by place of residence (U.S., state, and county), age, race (white, black, and other), gender, year, and underlying cause-of-death (4-digit ICD code or group of codes). There are 17 age groups: under 1 day, 1 -6 days, 7
-27 days, 28 -364 days, 1 -4 years, 5 -9 years, 10 -14 years, 15 -19 years, 20 -24 years, 25 -34 years, 35 -44 years, 45 -54 years, 55 -64 years, 65 -74 years, 75 -84 years, over 85 years, and unknown. We excluded infant deaths (age less than 1 year) and deaths at unknown ages. For each approximately 2-digit ICD9 code and year, we calculated two statistics: mean age at death 29 , and the fraction of deaths that occurred before age 65.
Data on the number of deaths, population, and the crude death rate, by age group for 1979 and 1998 are presented in Table 5 . The crude death rate declined in every age group except the highest (over 85 years). Despite this, the crude death rate for the entire population increased, due to aging of the population. The fraction of deaths occurring before age 65 decreased from 32% in 1979 to 24% in 1998. Figure 8 shows a comparison of mean age at death (from all causes) to life expectancy at birth over the period 1979-1997. 30 Life expectancy at birth is higher than mean age at death. For example, in 1997 life expectancy at birth was 76.5 years, and mean age at death was 71.9 years. However the 1979-1997 increase in mean age at death (4.0 years) was greater than the increase in life expectancy at birth (2.6 years).
Empirical Results
Estimates of equations (6) and (7) are presented in Table 6 . All equations are estimated via weighted least squares, where the weight is equal to the number of deaths.
In the first column, the dependent variable is mean age at death, drugs not labeled for a given indication are excluded, and we do not distinguish between priority-review and standard-review drugs. The coefficient on the total stock of drugs is positive but only marginally significant (p-value=.11). The second column is the same, except that unlabeled drugs listed in the NDDF Drug Indications Master Table are included. This has a modest positive effect on the point estimate of β, but reduces its standard error, so that the estimate is now highly significant (p-value=.02). This is consistent with the 30 Source: Anderson, Robert (1999). United States life tables, 1997. National vital statistics reports; vol 47 no. 28. Hyattsville, Maryland: National Center for Health Statistics. Life expectancy (e x )--the average number of years of life remaining for persons who have attained a given age (x)--is the most frequently used life table statistic. Calculation of the complete life table is derived from the probability of death (q x ), which depends on the number of deaths (D x ) and the midyear population (P x ) for each single year of age (x) observed during the calendar year of interest. There are two types of life tables-the generation or cohort life table and the current life table. The current life table (upon which these life expectancy figures are based) does not represent the mortality experience of an actual cohort. Rather, the current life table considers a hypothetical cohort and assumes that it is subject to the age-specific death rates observed for an actual population during a particular period. Thus, for example, a current life table for 1997 assumes a hypothetical cohort subject throughout its lifetime to the age-specific death rates prevailing for the actual population in 1997. The current life table may thus be characterized as rendering a ''snapshot'' of current mortality experience, and shows the long-range implications of a set of age-specific death rates that prevailed in a given year.
AMA Council on Scientific Affairs' observation that "the prevalence and clinical importance of prescribing drugs for unlabeled uses are substantial," and with the hypothesis that increases in the stock of (labeled and unlabeled) drugs to treat a condition increase the mean age at which people die from that cond ition.
In the equations reported in columns 3 and 4, the dependent variable is an alternative statistic of the age distribution of deaths: the fraction of deaths that occur before the age of 65. These estimates seem to confirm the estimates in the first two columns: when unlabeled indications are excluded, β is insignificantly different from zero, but when they are included, β is negative and highly significant, indicating that increases in the stock of drugs reduce the probability of dying before the age of 65.
In columns 5 and 6, the dependent variable is again mean age at death, but the stock of drugs is classified by therapeutic potential, i.e. disaggregated into priority-review and standard-review drugs. Whether or not unlabeled indications are included, β P (the coefficient on the stock of priority-review drugs) is positive and highly significant, and β S (the coefficient on the stock of standard-review drugs) is insignificantly different from zero. This is not surprising, since, as discussed earlier, priority-review drugs are those that represent a "significant improvement compared to marketed products, in the treatment, diagnosis, or prevention of a disease," while standard-review drugs are those that "appear to have therapeutic qualities similar to those of one or more already marketed drugs." Once again, the estimate of β P is larger and more significant when unlabeled indications are included than it is when they are excluded.
Columns 7 and 8 report analogous regressions, in which the dependent variable is the fraction of deaths that occur before the age of 65. Once again, we cannot reject the null hypothesis that the stock of standard-review drugs has no effect on mortality, but the hypothesis that the stock of priority-review drugs has no effect on mortality can be rejected, especially when unlabeled indications are included.
Since β S is not significant in any equation in columns 5-8, in columns 9-12 we estimate models that include only the stock of priority-review drugs. The estimates of β P in columns 9-12 are fairly similar to their counterparts in columns 5-8. We will use the estimate of β P in column 10 to evaluate the contribution of pharmaceutical knowledge-capital accumulation to the increase in the mean age at death during the period 1979-1998. Mean age at death increased by 3.8 years from 1979 to 1998: ∆AGE_DEATH = 3.8
years. The mean stock of priority-review drugs increased by 6.0 drugs: ∆PRI_STOCK = 6.0 drugs. The estimated contribution of the increase in the stock of priority-review drugs to the increase in mean age at death is β P * ∆PRI_STOCK = .065 * 6.0 = 0.39
years. The increase in the stock of priority-review drugs is estimated to have increased mean age at death by 0.39 years (4.7 months) during this period. Hence, about 10 percent of the total increase in mean age at death is due to the increase in the stock of priorityreview drugs.
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Now we will attempt to compare the value of the longevity benefit of pharmaceutical knowledge-capital accumulation to its cost. During the period 1979-1998, 508 NMEs (about 25/year) were approved by the FDA. The Office of Technology Assessment estimated that the average cost of an NME approval is $359 million, so the total cost of pharmaceutical knowledge-capital accumulation during the period was 508 NMES * $359 million/NME = $182 billion.
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The increase in the stock of priority-review drugs is estimated to have increased mean age at death by 0.39 years during this period. There are about 2 million deaths per year, so the total number of life-years gained per year is 0.39 * 2 million = 800,000 lifeyears/year. A number of authors have estimated that the value of a life-year is in the 31 These are weighted means, weighted by the number of deaths. 32 This estimate may be conservative, because it includes only the within-disease increase in mean age at death. We estimate that about 19% of the overall increase in mean age at death was due to a shift in the distribution of fatal diseases . Approval of new drugs may have contributed to this shift as well as to the within -disease increase in mean age at death. 33 This is the cost of all NMEs approved-both priority-review and standard-review. About 40% of NMEs are priority-review NMEs.
neighborhood of $150,000. Hence the value of the annual gain in life-years is 800,000 * $150,000 = $120 billion. Presumably, knowledge capital does not depreciate (although it can be rendered obsolete by future knowledge capital accumulation), so even if no new drugs were approved after 1998, people would continue to experience the 0.39-year higher life expectancy in all future years. In other words, the $120 billion may be viewed as an annuity.
As noted earlier (Figure 3) , DiMasi estimates that, in the last two decades, drug development has taken about 14 years. Suppose that the $182 billion in R&D expenditure is evenly distributed over an initial 14-year period, i.e. $13 billion/year in years 1-14. In year 15 and all future years, the population experiences a gain in life-years whose annual value is $120 billion. The internal rate of return to this series of cash flows is 18%.
Summary and Conclusions
People value leisure time as well as goods, so longevity increase is an important part of economic growth, broadly defined. R&D is the principal source of economic growth, and the pharmaceutical industry is the most R&D-intensive sector of the economy. In this paper we have assessed the contribution of pharmaceutical R&D to longevity increase (hence to economic growth), by analyzing the relationship between FDA approvals of new molecular entities and changes in the age distribution of deaths, using longitudinal disease-level data.
We computed the stock of drugs available (i.e., previously approved by the FDA)
to treat a given condition in a given year by combining FDA data with data from First DataBank's National Drug Data File. We used the CDC's Compressed Mortality File to measure changes in the age distribution of deaths, by cause of death.
The estimates indicated that approval of standard-review drugs-drugs whose therapeutic qualities the FDA considers to be similar to those of already marketed drugs-has no effect on longevity, but that approval of priority-review drugs-those considered by the FDA to offer significant improvement s in the treatment, diagnosis, or prevention of a disease-has a significant positive impact on longevity. Increases in the stock of (labeled and unlabeled) drugs to treat a condition increase the mean age at which people die from that condition, and reduce the probability of dying before the age of 65.
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